These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 2137217)
1. Plasma concentrations of remoxipride and the gastrointestinal transit of 111In-marked extended-release coated spheres. Graffner C; Wagner Z; Nilsson MI; Widerlöv E Pharm Res; 1990 Jan; 7(1):54-8. PubMed ID: 2137217 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of an oral controlled release formulation of remoxipride: a double-blind, crossover comparison with conventional formulation in chronic schizophrenics. Soni SD; Tench D; Ashwood TJ; Movin G Acta Psychiatr Scand Suppl; 1990; 358():45-7. PubMed ID: 1978487 [TBL] [Abstract][Full Text] [Related]
3. Steady-state pharmacokinetics of controlled release and immediate release formulations of remoxipride in patients with chronic schizophrenia. Tench D; Soni SD; Ashwood T; Movin G Psychopharmacology (Berl); 1990; 101(1):132-6. PubMed ID: 1971445 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of remoxipride controlled release and immediate release capsules in schizophrenic patients. Widerlöv E; Franzén G; Jansson P; Movin G Int Clin Psychopharmacol; 1990 Apr; 5(2):125-34. PubMed ID: 1974271 [TBL] [Abstract][Full Text] [Related]
5. Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. Wilding IR; Davis SS; Hardy JG; Robertson CS; John VA; Powell ML; Leal M; Lloyd P; Walker SM Br J Clin Pharmacol; 1991 Nov; 32(5):573-9. PubMed ID: 1954073 [TBL] [Abstract][Full Text] [Related]
6. In vivo validation of the release rate and palatability of remoxipride-modified release suspension. Sjöqvist R; Graffner C; Ekman I; Sinclair W; Woods JP Pharm Res; 1993 Jul; 10(7):1020-6. PubMed ID: 8378244 [TBL] [Abstract][Full Text] [Related]
7. Remoxipride--a new potential antipsychotic compound. Tolerability and pharmacokinetics after single oral and intravenous administration in healthy male volunteers. Grind M; Nilsson MI; Nilsson L; Oxenstierna G; Sedvall G; Wahlén A Psychopharmacology (Berl); 1989; 98(3):304-9. PubMed ID: 2568653 [TBL] [Abstract][Full Text] [Related]
8. Remoxipride: pharmacokinetics and effect on plasma prolactin. Movin-Osswald G; Hammarlund-Udenaes M Br J Clin Pharmacol; 1991 Sep; 32(3):355-60. PubMed ID: 1685665 [TBL] [Abstract][Full Text] [Related]
9. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers. Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557 [TBL] [Abstract][Full Text] [Related]
10. Critical dissolution tests of oral systems based on statistically designed experiments. II. In vitro optimization of screened variables on ER-coated spheres for the establishment of an in vitro/in vivo correlation. Abuzarur-Aloul R; Gjellan K; Sjölund M; Graffner C Drug Dev Ind Pharm; 1998 Mar; 24(3):203-12. PubMed ID: 9876576 [TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of remoxipride. von Bahr C; Movin G; Yisak WA; Jostell KG; Widman M Acta Psychiatr Scand Suppl; 1990; 358():41-4. PubMed ID: 1978486 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. Widerlöv E; Andersson U; von Bahr C; Nilsson MI Psychopharmacology (Berl); 1991; 103(1):46-9. PubMed ID: 1672458 [TBL] [Abstract][Full Text] [Related]
14. Remoxipride--a new potential antipsychotic drug. Pharmacological effects and pharmacokinetics following repeated oral administration in male volunteers. Farde L; Grind M; Nilsson MI; Ogenstad S; Sedvall G Psychopharmacology (Berl); 1988; 95(2):157-61. PubMed ID: 2901121 [TBL] [Abstract][Full Text] [Related]
15. Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture. Digenis GA; Sandefer EP; Page RC; Doll WJ; Gold TB; Darwazeh NB Pharm Res; 2000 May; 17(5):572-82. PubMed ID: 10888309 [TBL] [Abstract][Full Text] [Related]
16. Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. Stockis A; Sargentini-Maier ML; Otoul C; Connor A; Wilding I; Wray H Clin Ther; 2010 Sep; 32(10):1813-21. PubMed ID: 21194605 [TBL] [Abstract][Full Text] [Related]
17. Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets. Abrahamsson B; Alpsten M; Hugosson M; Jonsson UE; Sundgren M; Svenheden A; Tölli J Pharm Res; 1993 May; 10(5):709-14. PubMed ID: 8321836 [TBL] [Abstract][Full Text] [Related]
18. Effect of urinary pH on the plasma and urinary kinetics of remoxipride in man. Widerlöv E; Termander B; Nilsson MI Eur J Clin Pharmacol; 1989; 37(4):359-63. PubMed ID: 2574673 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of remoxipride in elderly psychotic patients. Movin G; Gustafson L; Franzén G; Widerlöv E; Soni SD; Tench D; Nilsson L; Yisak W Acta Psychiatr Scand Suppl; 1990; 358():176-80. PubMed ID: 1978480 [TBL] [Abstract][Full Text] [Related]